By SPC News Staff
The U.S. Court of Appeals for the Federal Circuit issued a decision recently upholding the validity of one of the patents for Novartis’ fingolimod (Gilenya), an immunosuppressive drug to treat flare-ups of multiple sclerosis.
With this decision, Novartis said it expects no generic versions of the drug in the U.S. market for at least the next two years.
U.S. Patent No. 9,187,405 (the ‘405 patent) covered a dosing regimen for fingolimod. In August 2020, the U.S. Federal